Understanding the epidemiological HIV risk factors and underlying risk context for youth residing in or originating from the Middle East and North Africa (MENA) region: A scoping r... by Roula Kteily-Hawa, Aceel Christina Hawa, David Gogolishvili, Mohammad Al Akel, Nicole Andruszkiewicz, Haran Vijayanathan, Mona Loutfy

Get full text

Scaling up access to antiretroviral treatment for HIV: lessons from a key populations program in Nigeria by Abdulsamad Salihu, Ibrahim Jahun, David Olusegun Oyedeji, Wole Fajemisin, Omokhudu Idogho, Samira Shehu, Aminu Yakubu, Jennifer Anyanti

Get full text

Firth's penalized logistic regression: A superior approach for analysis of data from India's National Mental Health Survey, 2016 by Satish Suhas, Narayana Manjunatha, Channaveerachari Naveen Kumar, Vivek Benegal, Girish N. Rao, Mathew Varghese, Gopalkrishna Gururaj

Get full text

Exploring Traditional Knowledge and Potential Uses of Local Freshwater Algae and Aquatic Plants in Thai Wetland Communities by Pasin Norkum Ai, Angkhana Inta, Sarana Rose Sommano, Kittiya Phinyo, Kritsana Duangjan, Tibet Tangpao

Get full text

E.V. From ‘Greater’ to ‘Global Britain’: The New and the Old in the Foreign Policy of the United Kingdom by E. V. Khakhalkina

Get full text

A humanized anti-MSLN×4-1BB bispecific antibody exhibits potent antitumour activity through 4-1BB signaling activation and fc function without systemic toxicity by Da-yan Zhang, Zhi-hua Zhang, Wen-ting Liu, Wei-ming Zhou, Peng-fei Zhou, Juan-juan Wei, Xue-jing Dai, Xiao-li Zeng, Yu-qiong Zhou, Han-wang Li, Heng Zhang, Ao-lin Shen, Lian-sheng Cheng, Guo-dong Shen, Yi-fu He

“…In addition, the mean half-life of HK013-G1 was approximately 61 and 97 h at single doses of 3 and 30 mg/kg, respectively. Conclusion The optimal anti-MSLN×4-1BB bsAb HK013-G1 exhibited synergistic antitumour effects by inducing an ADCC effect (innate immunity) and stimulating the 4-1BB signaling pathway (adaptive immunity) upon cross-bridging with MSLN with no systemic toxicity, which may offer the promise of an improved therapeutic window relative to that of 4-1BB agonists.…”
Get full text

Contextual Vulnerability Should Guide Fair Subject Selection in Xenotransplantation Clinical Trials by Gianna Strand

“…This potential subject population includes individuals with broadly reactive antibodies who are unlikely to match to a donor organ and individuals with anatomical contraindications who face prohibitive risks with standard allografts or bridging therapies.…”
Get full text